Role of angiotensin and endothelin in testicular ischemia reperfusion injury

International Journal of Urology

Volumn 19, Issue 3, 2012, Pages 257-263

  Turkili, Burak ^a   Kurcer, Zehra ^a   Dengiz, Gunnur Ozbakis ^a   Kandemir, Nilufer Onak ^a   Mungan, Gorkem ^a   Ozacmak, Veysel Haktan ^a   Banoglu, Zekiye Nur ^a  

^a ZONGULDAK KARAELMAS UNIVERSITY   (Turkey)

Author keywords

Bosentan; Enalapril; Ischemia reperfusion injury; Losartan; Testis

Indexed keywords

ANGIOTENSIN; BOSENTAN; ENALAPRIL; ENDOTHELIN; LOSARTAN; MALONALDEHYDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERY OCCLUSION; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; HISTOLOGY; HISTOPATHOLOGY; ISCHEMIA; MALE; NONHUMAN; ORCHIECTOMY; PRIORITY JOURNAL; RAT; REPERFUSION INJURY; TESTIS DISEASE; TESTIS ISCHEMIA; VEIN OCCLUSION;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANGIOTENSINS; ANIMALS; ENALAPRIL; ENDOTHELINS; LOSARTAN; MALE; MALONDIALDEHYDE; RATS; RATS, WISTAR; RECEPTORS, ENDOTHELIN; REPERFUSION INJURY; STATISTICS, NONPARAMETRIC; SULFONAMIDES; TESTIS;

EID: 84857363896     PISSN: 09198172     EISSN: 14422042     Source Type: Journal    
DOI: 10.1111/j.1442-2042.2011.02924.x     Document Type: Article

References (61)

1. Ringdahl E, Teague L. Testicular torsion. Am. Fam. Physician 2006; 74: 1739-43.
2. Akgun FM, Kilinc K, Aktuǧ T. Reperfusion injury after detorsion of unilateral testicular torsion. Urol. Res. 1993; 21: 395-9.
3. Kehinde EO, Anim JT, Mojiminiyi OA, Al-Awadi F, Omu AE, Varghese R. Significance of determining the point of reperfusion failure in experimental torsion of testis. Int. J. Urol. 2005; 12: 81-9.
4. Somuncu S, Cakmak M, Erdogan S, Caglayan O, Akman H, Kaya M. Protective effects of trapidil in ischemia-reperfusion injury due to testicular torsion and detorsion: an experimental study. Int. J. Urol. 2006; 13: 601-5.
5. Good JM, Nihoyannopoulos P, Ghatei MA etal. Elevated plasma endothelin concentrations in heart failure; an effect of angiotensin II. Eur. Heart J. 1994; 15: 1634-40.
6. Sigurdsson A, Held P, Swedberg K. Short- and long-term neurohormonal activation following acute myocardial infarction. Am. Heart J. 1993; 126: 1068-76.
7. Masuko H, Jin MB, Horiuchi H etal. Protective effect of agiotensin II type I receptor antagonist, CV-11974, on ischemia and reperfusion injury of the liver. Transplantation 2001; 71: 1034-39.
8. Timmermans V, Peake PW, Charlesworth JA, Macdonald GJ, Pawlak MA. Angiotensin II receptor regulation in anti-glomerular basement membrane nephritis. Kidney Int. 1990; 38: 518-24.
9. 1 receptor-mediated contraction in rats. Stroke 2004; 35: 970-4.
10. Konstam MA. Role of angiotensin converting enzyme inhibitors in preventing left ventricular remodelling following myocardial infarction. Eur. Heart J. 1995; 16 (Suppl K): 42-8.
11. Przyklenk K, Kloner RA. "Cardioprotection" by ACE-inhibitors in acute myocardial ischemia and infarction. Basic Res. Cardiol. 1993; 88: 139-54.
12. Ozer MK, Sahna E, Birincioglu M, Acet A. Effects of captopril and losartan on myocardial ischemia-reperfusion induced arrhythmias and necrosis in rats. Pharmacol. Res. 2002; 45: 257-63.
13. Araya J, Tsuruma T, Hirata K, Yagihashi A, Watanabe N. TCV-116, an angiotensin II type 1 receptor antagonist, reduces hepatic ischemia-reperfusion injury in rats. Transplantation 2002; 73: 529-34.
14. Jerkic M, Miloradovic Z, Jovovic D etal. Relative roles of endothelin-1 and angiotensin II in Experimental post-ischaemic acute renal failure. Nephrol. Dial. Transplant. 2004; 19: 83-94.
15. Seujang Y, Kittikowit W, Eiam-Ong S, Eiam-Ong S. Lipid peroxidation and renal injury in renal ischemic reperfusion: effect of angiotensin inhibition. J. Med. Assoc. Thai. 2006; 89: 1686-93.
16. Salcedo A, Fernández N, García Villalón AL, Monge L, Narváez Sánchez R, Diéguez G. Role of angiotensin II in the response to endothelin-1 of goat cerebral arteries after ischemia-reperfusion. Vasc. Pharmacol. 2009; 50: 160-5.
17. Takagi T, Yoshida N, Isozaki Y etal. CV-11974, angiotensin II type I receptor antagonist, protects against ischemia-reperfusion injury of the small intestine in rats. Eur. J. Pharmacol. 2006; 535: 283-90.
18. Gokce G, Karboga H, Yildiz E, Ayan S, Gultekin Y. Effect of angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade on apoptotic changes in contralateral testis following unilateral testicular torsion. Int. Urol. Nephrol. 2008; 40: 989-5.
19. Yanagisawa M, Kurihara H, Kimura S etal. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988; 332: 411-15.
20. Laplante MA, de Champlain J. The interrelation of the angiotensin and endothelin systems on the modulation of NAD(P)H oxidase. Can. J. Physiol. Pharm. 2006; 84: 21-8.
21. Brunner F, Kukovetz WR. Postischemic antiarrhythmic effects of angiotensin converting enzym inhibitors. Role of suppresion of endogenous endothelin secretion. Circulation 1996; 94: 1752-61.
22. A receptor antagonism limits the brain damage after ischemic stroke in rat. Eur. J. Pharmacol. 2007; 570: 142-8.
23. Grover GJ, Dzwonczyk S, Parham CS. The endothelin-1 receptor antagonist BQ-123 reduces infarct size in a canine model of coronary occlusion and reperfusion. Cardiovasc. Res. 1993; 27: 1613-18.
24. Uhlmann D, Uhlmann S, Löffler BM, Witzigmann H, Spiegel HU. Pharmacological regulation of postischemic sinusoidal diameters in rats - a new approach for reducing hepatic ischemia/reperfusion injury. Clin. Hemorheol. Microcirc. 2001; 24: 233-46.
25. Kusumoto K, Kubo K, Kandori H etal. Effects of a new endothelin antagonist, TAK-044, on post-ischemic acute renal failure in rats. Life Sci. 1994; 55: 301-10.
26. Herbert KJ, Hickey MJ, Lepore DA, Knight KR, Morrison WA, Stewart AG. Effects of the endothelin receptor antagonist Bosentan on ischaemia reperfusion injury in rat skeletal muscle. Eur. J. Pharmacol. 2001; 424: 59-67.
27. Minutoli L, Antonuccio P, Romeo C etal. Evidence for a role of mitogen-activated protein kinase 3/mitogen-activated protein kinase in the development of testicular ischemia-reperfusion injury. Biol. Reprod. 2005; 73: 730-6.
28. Seljeskog E, Hervig T, Mansoor MA. A novel HPLC method for the measurement of thiobarbituric acid reactive substances (TBARS). A comparison with a commercially available kit. Clin. Biochem. 2006; 39: 947-4.
29. Johnsen SG. Testicular biopsy score count-a method for registration of spermatogenesis in human testes: normal values and results of 335 hypogonadal males. Hormones 1970; 1: 2-25.
30. de Kretser DM, Holstein AF. Testicular biopsy and abnormal germ cells. In: Hafez ESE (ed.). Human Semen and Fertility Regulation in Men. Mosby, St. Louis, MO, 1976; 332-43.
31. Rossi F, Ferraresi{dotless} A, Romagni P, Silvestroni L, Santiemma V. Angiotensin II stimulates contraction and growth of testicular peritubular myoid cells in vitro. Endocrinology 2002; 143: 3096-104.
32. Kanehara H, Song K, Hirai K etal. Involvement of angiotensin II receptor subtypes during testicular development in rats. Int. J. Androl. 1998; 21: 186-95.
33. Alenina N, Baranova T, Smirnow E etal. Cell type-specific expression of the Mas proto-oncogene in testis. J. Histochem. Cytochem. 2002; 50: 691-6.
34. Sakaguchi K, Jackson B, Chai SY, Mendelsohn FA, Johnson CI. Effects of perindopril on tissue angiotensin-converting enzyme activity demonstrated by quantitative in vitro autoradiography. J. Cardiovasc. Pharmacol. 1988; 12: 710-17.
35. Santiemma V, Beligotti F, Magnanti M, Palleschi S, Silvestroni L, Fabbrini A. Endothelin-1 stimulates deoxyribonucleic acid synthesis and contraction in testicular peritubular myoid cells. Biol. Reprod. 1996; 54: 583-90.
36. Maggi M, Barni T, Orlando C etal. Endothelin-1 and its receptors in human testis. J. Androl. 1995; 16: 213-24.
37. Ergun S, Harneit S, Paust HJ, Mukhopadhyay AK, Holstein AF. Endothelin and endothelin receptors A and B in the human testis. Anat. Embryol. 1999; 199: 207-14.
38. Peri A, Fantoni G, Granchi S etal. Gene expression of endothelin-1, endothelin-converting enzyme-1, and endothelin receptors in human epididymis. J. Clin. Endocrinol. Metab. 1997; 82: 3797-806.
39. Siragy HMAT. 1) and AT(2) receptors in the kidney: role in disease and treatment. Am. J. Kidney Dis. 2000; 36: 4-9.
40. Wu L, Iwai M, Nakagami H etal. Roles of angiotensin II type 2 receptor stimulation associated with selective angiotensin II type 1 receptor blockade with valsartan in the improvement of inflammation-induced vascular injury. Circulation 2001; 104: 2716-21.
41. Nio Y, Matsubara H, Murasawa S, Kanasaki M, Inada M. Regulation of gene transcription of angiotensin II receptor subtypes in myocardial infarction. J. Clin. Invest. 1995; 95: 46 -54.
42. Burnier M. Angiotensin II type 1 receptor blockers. Circulation 2001; 103: 904-12.
43. Farre AL, Riesco A, Espinosa G etal. Effect of endothelin-1 on neutrophil adhesion to endothelial cells and perfused heart. Circulation 1993; 88: 1166-71.
44. Elmarakby AA, Loomis ED, Pollock JS, Pollock DM. NADPH oxidase inhibition attenuates oxidative stress but not hypertension produced by chronic ET-1. Hypertension 2005; 45: 283-7.
45. Kähler J, Ewert A, Weckmüller J etal. Oxidative stress increases endothelin-1 synthesis in human coronary artery smooth muscle cells. J. Cardiovasc. Pharmacol. 2001; 38: 49-57.
46. Yang TL, Chen MF, Jiang JL, Xie QY, Li YP, Li YJ. The endothelin receptor antagonist decreases ischemia/reperfusion-induced tumor necrosis factor production in isolated rat hearts. Int. J. Cardiol. 2005; 100: 495-8.
47. Lysiak JJ, Turner SD, Nguyen QAT, Singbartl K, Ley K, Turner TT. Essential role of neutrophils in germ cell-specific apoptosis following ischemia/reperfusion of the mouse testis. Biol. Reprod. 2001; 65: 718 -25.
48. B endothelin receptor antagonist, attenuated oxidative stress after experimental myocardial ischemia and reperfusion. Mol. Cell. Biochem. 2005; 275: 67-74.
49. 1-receptor inhibition on postischemic injury and leukocyte adherence in vivo and in vitro. Shock 2000; 13: 190-6.
50. Kurcer Z, Oguz E, Ozbilge H, Baba F, Aksoy N, Celik N. Effect of melatonin on testicular ischemia/reperfusion injury in rats: is this effect related to the proinflammatory cytokines? Fertil. Steril. 2008; 89 (5 Suppl): 1468-73.
51. Cushman DW, Wang FL, Fung WC etal. Comparison in vitro, ex vivo and in vivo of the actions of seven structurally diverse inhibitors of angiotensin converting enzyme (ACE). Br. J. Clin. Pharmacol. 1989; 28: 115S-30S.
52. Chopra M, Beswick H, Clapperton M, Dargie HJ, Smith WE, McMurray J. Antioxidant effects of angiotensin converting enzyme (ACE) inhibitors: free radical and oxidant scavenging are sulfhydryl dependent, but lipid peroxidation is inhibited by both sulfhydryland nonsulfhydryl-containing ACE inhibitors. J. Cardiovasc. Pharmacol. 1992; 19: 330-40.
53. Mak IT, Freedman AM, Dickens BF, Weglicki WB. Protective effects of sulfhydryl-containing angiotensin-converting enzyme inhibitors against free radical injury in endothelial cells. Biochem. Pharmacol. 1990; 40: 2169- 75.
54. Goldschmidt JE, Tallarida RJ. Pharmacological evidence that captopril possesses an endothelium-mediated component of vasodilation: effect of sulfhydryl groups on endothelium-derived relaxing factor. J. Pharmacol. Exp. Ther. 1991; 257: 1136-45.
55. de Cavanagh EM, Inserra F, Ferder L, Romano L, Ercole L, Fraga CG. Superoxide dismutase and glutathione peroxidase activities are increased by enalapril and captopril in mouse liver. FEBS Lett. 1995; 361: 22-4.
56. Khaper N, Singal PK. Modulation of oxidative stress by a selective inhibition of angiotensin II type 1 receptors in MI rats. J. Am. Cell. Cardiol. 2001; 37: 1461-66.
57. Rajagopalan S, Kurz S, Munzel T etal. Angiotensin II mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone. J. Clin. Invest. 1996; 97: 1916-23.
58. Singh AD, Amit S, Kumar OS, Rajan M, Mukesh N. Cardioprotective effects of bosentan, a mixed endothelin type A and B receptor antagonist, during myocardial ischaemia and reperfusion in rats. Basic Clin. Pharmacol. Toxicol. 2006; 98: 604-10.
59. Bien S, Riad A, Ritter CA etal. The endothelin receptor blocker bosentan inhibits doxorubicin-induced cardiomyopathy. Cancer Res. 2007; 67: 10428-35.
60. A) receptor antagonist (BQ-123) reduces both myocardial infarct size and oxidant injury. Toxicology 2006; 219: 142-9.
61. Pourdjabbar A, Parker TG, Nguyen QT etal. Effects of pre-, peri-, and postmyocardial infarction treatment with losartan in rats: effect of dose on survival, ventricular arrhythmias, function, and remodeling. Am. J. Physiol. Heart Circ. Physiol. 2005; 288: H1997-2005.